Provided by Tiger Fintech (Singapore) Pte. Ltd.

Aprea Therapeutics, Inc.

1.70
+0.01020.60%
Volume:18.89K
Turnover:32.27K
Market Cap:9.40M
PE:-0.72
High:1.77
Open:1.70
Low:1.68
Close:1.69
Loading ...

Aprea Says APR-1051 Shows Early Disease Control in HPV-Positive Head and Neck Cancer

MT Newswires Live
·
25 Jun

Aprea Therapeutics announces new preclinical data, update on APR-1051

TIPRANKS
·
25 Jun

BRIEF-Aprea Reports Promising Early Data for WEE1 Inhibitor in HPV+ HNSCC with MD Anderson

Reuters
·
25 Jun

Aprea Therapeutics Inc - Phase 1 Update Shows Early Disease Control in Hpv+ Patient

THOMSON REUTERS
·
25 Jun

Aprea Reports Anti-Proliferative Results and Promising Early-Stage Clinical Data for Next-Generation Wee1 Inhibitor, Apr-1051, in Hpv+ Head and Neck Squamous Cell Carcinoma (Hnscc) in Collaboration With Md Anderson Cancer Center

THOMSON REUTERS
·
25 Jun

Aprea Therapeutics Inc. Conducted Annual Stockholder Meeting

Reuters
·
10 Jun

Aprea Therapeutics Reports First Quarter 2025 Financial Results and Provides a Clinical Update

THOMSON REUTERS
·
14 May

Aprea Therapeutics Q1 EPS USD -0.66

THOMSON REUTERS
·
14 May

Aprea Therapeutics Inc expected to post a loss of 86 cents a share - Earnings Preview

Reuters
·
10 May

Aprea Therapeutics Inc -Open Label Data From Study Are Expected in Second Half of 2025

THOMSON REUTERS
·
31 Mar

Aprea Therapeutics Inc -Dosing of Patient With Hpv+ Head and Neck Squamous Cell Carcinoma (Hnscc) in Ongoing Acesot-1051 Trial

THOMSON REUTERS
·
31 Mar

Aprea Therapeutics Full Year 2024 Earnings: Beats Expectations

Simply Wall St.
·
26 Mar

Aprea Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
25 Mar

Aprea Therapeutics Q4 EPS ($0.49) Up From ($0.92) YoY.

Benzinga
·
25 Mar

Aprea Therapeutics Inc expected to post a loss of 69 cents a share - Earnings Preview

Reuters
·
21 Mar

BRIEF-Aprea Therapeutics Announces Agreement With MD Anderson Cancer Center To Explore Apr-1051 As A Potential Treatment For Head And Neck Squamous Cell Carcinoma (Hnscc)

Reuters
·
11 Mar

Aprea Therapeutics provides update on existing patent portfolio

TipRanks
·
06 Feb

Aprea Therapeutics Announces Strategic Ip Portfolio Evolution in DNA Damage Response (Ddr) Cancer Therapeutics

THOMSON REUTERS
·
05 Feb